Cargando…

Mosapride combined with probiotics on gastrointestinal function and growth in premature infants

The aim of this study was to investigate the effects of mosapride combined with probiotics on gastrointestinal function and growth and development in premature infants. A total of 240 premature infants treated at Weifang People's Hospital between June 2012 and May 2015 who matched our criteria...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ai-Mei, Sun, Zhi-Qun, Zhang, Li-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450587/
https://www.ncbi.nlm.nih.gov/pubmed/28587329
http://dx.doi.org/10.3892/etm.2017.4340
_version_ 1783240010855612416
author Zhang, Ai-Mei
Sun, Zhi-Qun
Zhang, Li-Ming
author_facet Zhang, Ai-Mei
Sun, Zhi-Qun
Zhang, Li-Ming
author_sort Zhang, Ai-Mei
collection PubMed
description The aim of this study was to investigate the effects of mosapride combined with probiotics on gastrointestinal function and growth and development in premature infants. A total of 240 premature infants treated at Weifang People's Hospital between June 2012 and May 2015 who matched our criteria were randomly divided into three groups of 80 cases each. Group A received routine treatment, group B received routine treatment combined with live B. subtilis and E. faecium granules with multivitamins (Medilac-Vita), and group C received routine treatment and Saccharomyces boulardii sachets (Bioflor). Mosapride was administered to patients in groups B and C to promote intestinal peristalsis. Gastrin and bilirubin levels, as well as jaundice fade time, were recorded. Growth and development condition (i.e., head circumference and weight), duration and incidence of feeding intolerance (FI), as well as other symptoms were also analyzed. By day 14, gastrin concentrations in groups B and C were significantly higher than those in group A (P<0.05). Serum bilirubin levels in groups B and C showed a progressive decline from day 7 to day 14, and jaundice duration in group A was significantly longer (P<0.05). Furthermore, at 2 weeks, the average weight growth rate and head circumference were significantly greater in groups B and C, weight loss recovery time was shorter, and EUGR incidence was lower (P<0.05). The incidence rate of gastric retention and FI were lower in groups B and C than group A (P<0.05), and neonatal hyperbilirubinemia, parenteral nutrition-associated cholestasis, necrotizing enterocolitis, and neonatal sepsis incidence was significantly lower in groups B and C (P<0.05). Mosapride combined with probiotics can effectively reduce FI incidence in premature infants, shorten enteral feeding time, promote the absorption of required nutrients, and promote the development and recovery of early physiological weight loss in preterm infants.
format Online
Article
Text
id pubmed-5450587
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-54505872017-06-05 Mosapride combined with probiotics on gastrointestinal function and growth in premature infants Zhang, Ai-Mei Sun, Zhi-Qun Zhang, Li-Ming Exp Ther Med Articles The aim of this study was to investigate the effects of mosapride combined with probiotics on gastrointestinal function and growth and development in premature infants. A total of 240 premature infants treated at Weifang People's Hospital between June 2012 and May 2015 who matched our criteria were randomly divided into three groups of 80 cases each. Group A received routine treatment, group B received routine treatment combined with live B. subtilis and E. faecium granules with multivitamins (Medilac-Vita), and group C received routine treatment and Saccharomyces boulardii sachets (Bioflor). Mosapride was administered to patients in groups B and C to promote intestinal peristalsis. Gastrin and bilirubin levels, as well as jaundice fade time, were recorded. Growth and development condition (i.e., head circumference and weight), duration and incidence of feeding intolerance (FI), as well as other symptoms were also analyzed. By day 14, gastrin concentrations in groups B and C were significantly higher than those in group A (P<0.05). Serum bilirubin levels in groups B and C showed a progressive decline from day 7 to day 14, and jaundice duration in group A was significantly longer (P<0.05). Furthermore, at 2 weeks, the average weight growth rate and head circumference were significantly greater in groups B and C, weight loss recovery time was shorter, and EUGR incidence was lower (P<0.05). The incidence rate of gastric retention and FI were lower in groups B and C than group A (P<0.05), and neonatal hyperbilirubinemia, parenteral nutrition-associated cholestasis, necrotizing enterocolitis, and neonatal sepsis incidence was significantly lower in groups B and C (P<0.05). Mosapride combined with probiotics can effectively reduce FI incidence in premature infants, shorten enteral feeding time, promote the absorption of required nutrients, and promote the development and recovery of early physiological weight loss in preterm infants. D.A. Spandidos 2017-06 2017-04-13 /pmc/articles/PMC5450587/ /pubmed/28587329 http://dx.doi.org/10.3892/etm.2017.4340 Text en Copyright: © Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Zhang, Ai-Mei
Sun, Zhi-Qun
Zhang, Li-Ming
Mosapride combined with probiotics on gastrointestinal function and growth in premature infants
title Mosapride combined with probiotics on gastrointestinal function and growth in premature infants
title_full Mosapride combined with probiotics on gastrointestinal function and growth in premature infants
title_fullStr Mosapride combined with probiotics on gastrointestinal function and growth in premature infants
title_full_unstemmed Mosapride combined with probiotics on gastrointestinal function and growth in premature infants
title_short Mosapride combined with probiotics on gastrointestinal function and growth in premature infants
title_sort mosapride combined with probiotics on gastrointestinal function and growth in premature infants
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450587/
https://www.ncbi.nlm.nih.gov/pubmed/28587329
http://dx.doi.org/10.3892/etm.2017.4340
work_keys_str_mv AT zhangaimei mosapridecombinedwithprobioticsongastrointestinalfunctionandgrowthinprematureinfants
AT sunzhiqun mosapridecombinedwithprobioticsongastrointestinalfunctionandgrowthinprematureinfants
AT zhangliming mosapridecombinedwithprobioticsongastrointestinalfunctionandgrowthinprematureinfants